Evidence map›Paper›PMID 42835535›Full record

ArticleIranian journal of medical sciences2026

A Retrospective Post-Marketing Surveillance Study on TGlobulin25

Mojtaba Shafiekhani, Mohammad Amin Jafarzadeh, Farbod Shahabinezhad, Siavash Gholami, Jamshid Roozbeh, Zahra Zare, Sahand Mohammadzadeh, Marziyeh Doostfatemeh, Saman Nikeghbalian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mojtaba ShafiekhaniDepartment of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Amin JafarzadehStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Farbod ShahabinezhadDepartment of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Siavash GholamiShiraz Transplant Center, Abu-Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Jamshid RoozbehShiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra ZareShiraz Transplant Center, Abu-Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Sahand MohammadzadehDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Marziyeh DoostfatemehDepartment of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Saman NikeghbalianShiraz Transplant Center, Abu-Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Post-marketing surveillance studies are essential to establish a realistic assessment of TGlobulin25 Methods: A comparative study of recipients who received either TGlobulin25 Results: A total of 247 patients were enrolled (118 received TGlobulin25 Conclusion: Overall, no statistically significant differences were observed in major efficacy and safety outcomes. However, eGFR at 12 months was higher in the TGlobulin25

Indexed as

Antilymphocyte SerumGraft RejectionKidney TransplantationProduct Surveillance, PostmarketingAdultAnimalsFemaleHumansImmunosuppressive AgentsIranMaleMiddle AgedRabbitsRetrospective StudiesAntilymphocyte SerumImmunosuppressive AgentsthymoglobulinKidney Transplantationrabbit ATGSolid Organ TransplantationThymoglobulin

Identifiers

PMID42835535
PMCPMC13635453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.